HMPL-306
A Phase 1, Open-Label, Multicenter Study of HMPL-306 in Advanced Hematological Malignancies With Isocitrate Dehydrogenase (IDH) Mutations
More Information
- Trial Status
- Accepting patients
- Trial Phase
- Phase 1
- Enrollment
- 75 patients (estimated)
- Sponsors
- Hutchmed
- Tags
- Isocitrate Dehydrogenase 1 (IDH1) Inhibitor, MIDH2 Inhibitor
- Trial Type
- Treatment
- Last Update
- 1 week ago
- SparkCures ID
- 1699
- NCT Identifier
- NCT04764474
Real People. Real Support.
Need help connecting with this clinical trial? We're here to help!
Print this trial to share with your doctor.
We can help answer any questions and connect you (or your patient) with the study team.
Schedule a time that is convenient and we’ll call you to see how we can help you and your patient.